KRAS and cancer: Uromonitor is a test for detecting mutations in the TERTp and FGFR3 genes in the DNA of cancer cells present in urine, based on real-time PCR technology. The urine filtration system allows for pre-processing and preservation of the sample. In the validation study, Uromonitor achieved 73.5% SN and 73.2% specificity in detecting BCa recurrence, which was similar to the results of cystoscopy.Uromonitor-V2, which adds detection of mutations in the KRAS gene, achieved 100% SN and 83.3% specificity in the group of patients with NMIBCa, making it an effective tool for monitoring BCa.